In 2013, rapid translational research led to the first clinical validation of cabozantinib use in a biomarker-selected population with RET-altered tumors, less than 2 years following initial identification of RET fusions as oncogenic drivers in patients with NSCLC [30,32,56]. The gene discussed is RET; the disease is non-small cell lung carcinoma.